Home › Companies › ANIX

Anixa Biosciences

ANIX Lead: Phase 1 ★ Read the deep dive → 1 Biotech Distilled article ↓

Oncology Cell Protein

Most recent annual filing: 2026-01-12

Pipeline (3 active programs)

liraltagene autoleucel

liraltagene-autoleucel · lira-cel

Cell Target: FSH-Receptor, FSHR

Ovarian Cancer Phase 1 H. Lee Moffitt Cancer Center and Research Institute

alpha-lactalbumin vaccine

Protein Target: alpha-lactalbumin

Breast Cancer Phase 1 Cleveland Clinic NCT04674306

AMHR2-ED vaccine

Protein Target: AMHR2-ED

Ovarian Cancer Preclinical Cleveland Clinic

Biotech Distilled coverage (1)

2026-07-31 Anixa Biosciences (ANIX) — Scientific Deep Dive for Lira-cel, the α-Lactalbumin Vaccine, and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.